- Details
- Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. Dr. Iravani presents a patient case to illustrate challenges faced in treatment progression, highlighting the patient’s journey through various therapies inclu...
|
- Details
- Dan George discusses the collaborative effort in managing PLUVICTO® therapy for prostate cancer with team members Kristen Davis, a Physician Assistant, and Sarah Wood, a Nurse Practitioner. Kristen describes the meticulous process of vetting patients for PLUVICTO® therapy, which includes reviewing patient information, scans, and coordinating with various departments for approval. Sarah outlines he...
|
- Details
- Phillip Koo engages in a conversation with Ephraim Parent on the pivotal role of PSMA PET imaging in selecting patients for radioligand therapy (RLT). Dr. Parent emphasizes the critical importance of accurately identifying patients through PSMA PET imaging to ensure successful outcomes with Pluvicto therapy. He outlines the standardized practice of evaluating patients with PSMA PET to detect PSMA-...
|
- Details
- Alicia Morgans interviews Matthew Rettig about the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) within the veterans' healthcare system. Dr. Rettig highlights the VA's infrastructure that supports comprehensive care, including genetic analyses, access to a wide range of medications, and innovative telehealth programs that extend expert care to veterans in...
|
- Details
- Evan Yu and Oliver Sartor discuss the VISION trial's exploration of predictive and prognostic markers in the treatment of prostate cancer with Lutetium-PSMA-617. Sartor clarifies the distinction between predictive and prognostic markers, emphasizing the trial's focus on baseline markers and their association with treatment outcomes. The conversation highlights the importance of PSMA PET scans in p...
|
- Details
- Alicia Morgans engages in a conversation with Oliver Sartor about the evolving landscape of Radioligand Therapy in metastatic castration-resistant prostate cancer (mCRPC). Dr. Sartor discusses the trials in progress for each PSMAfore, SPLASH, and ECLIPSE trials. Dr. Sartor notes the trials are not complete and with little to no data the treatments are not yet ready for widespread clinical applicat...
|
- Details
- Jeremie Calais joins Phillip Koo on UroToday where they discuss the first annual PSMA conference hosted by UCLA and UCSF in partnership with Prostate Cancer Foundation. (PCF). The conference topics include PSMA theranostics in prostate cancer and aim to leverage early experiences and global collaborations in PSMA clinical use. It featured a multidisciplinary panel of experts from around the world,...
|
- Details
- Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the field. Initially specializing in nuclear cardiology in Canada, she shifted to theranostics and nuclear medicine, driven by the dynamic growth in these areas. Dr. Emmett discusses the challenges and excitement of running clinical...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with lut...
|
- Details
- Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 partic...
|
